Key Highlights

  • SciSparc Ltd. (NASDAQ:SPRC) rose 55.96% to USD 1.70 in early trading on Monday, October 26, 2026, after a shift in strategic focus from cannabinoid drugs towards agentic artificial intelligence.
  • The company announced its transformation on Thursday, October 15, 2026, and repeated the focus on cybersecurity and finance technologies in a release on Monday, October 19, 2026.
  • Subsidiary NeuroThera Labs Inc. reported positive progress in an FDA-approved Phase IIb trial for Tourette syndrome in a release dated Thursday, October 22, 2026.
  • The company states that there is no assurance the AI plan will lead to any transaction, commercial agreement or revenue, which leaves the rise resting on sentiment.

SciSparc (NASDAQ:SPRC): an AI pivot meets a thin market

SciSparc Ltd. (NASDAQ:SPRC), a specialty pharmaceutical group developing cannabinoid-based drugs, rose 55.96% to USD 1.70 in early trading on Monday, October 26, 2026. The company has not issued a release dated Monday that explains the move. The most relevant recent news is the strategic shift announced on Thursday, October 15, 2026 and restated on Monday, October 19, 2026, in which the company said it would focus on agentic AI-powered technologies, meaning software that plans and acts with limited human input, including cybersecurity and finance applications. The release recorded a July 27, 2026 decision to target the sector and the creation of a scientific advisory board for AI and cybersecurity on August 26, 2026. The implied prior close is about USD 1.09.

Why an AI Label Can Move a Small Drug Developer

A change of focus towards a popular theme often draws momentum buyers to small listed companies, because the label can lift a valuation before any revenue exists. SciSparc (NASDAQ:SPRC) says it will evaluate technologies, companies and opportunities across the agentic AI ecosystem, which is an intention rather than a transaction. Its existing business sits in NeuroThera Labs Inc., a clinical-stage subsidiary listed on the TSX Venture Exchange under NTLX, which develops SCI-110 for Tourette syndrome, Alzheimer's disease and agitation and SCI-210 for autism spectrum disorder and status epilepticus. A subsidiary also sells hemp seed oil products through an online marketplace. A release of Thursday, October 22, 2026 reported positive progress in the Phase IIb Tourette trial, which kept the drug story in view alongside the AI plan.

Risks and What to Watch

The principal risk is that the pivot produces no acquisition, contract or revenue, as the company itself cautions. Small-cap shares that rise more than 50% in a session often retrace when buying momentum fades, and the move above USD 1.00 does not remove the need for the company to fund both a drug pipeline and a new strategy. Shareholders should also consider dilution, because small companies frequently raise capital after sharp rallies, although the company has not announced any offering in its recent releases. The Annual Report on Form 20-F, filed with the SEC on April 29, 2026, remains the reference for cash and share count. The Federal Reserve decides on Wednesday, October 28, 2026, which can affect speculative shares.

Where Things Stand

The answer is that SciSparc Ltd. (NASDAQ:SPRC) rose 55.96% to USD 1.70 because investors are pricing a change of strategy rather than any completed deal, and the company has not issued a release explaining Monday's move. The AI plan covers cybersecurity and finance but carries no stated transaction, while the Tourette programme at NeuroThera Labs continues. The next catalysts are any definitive AI transaction, further NeuroThera trial updates and the Federal Reserve decision on Wednesday, October 28, 2026. Share prices of small companies can reverse quickly, and this is not investment advice.